Pileseptin Gel now available at Tamro central warehouse
Double Bond Pharmaceuticals subsidiary Drugsson AB, distributor of Pileseptin on the Nordic market, has received its first delivery of Pilseptin gel to Sweden. The products are stored at Tamro who is Drugsson’s partner for warehousing and logistics. Pileseptin Gel is manufactured in France and will be available for the Swedish market at Meds.se and Apotek365 soon. Pileseptin Spray is available for purchase in Sweden through Apotek365 since 21stof January 2019 (https://mb.cision.com/Main/12720/2722391/979480.pdf ). At the same time, Drugsson AB is working to sell these products to more web-based and physical pharmacies.
"We are pleased that Pileseptin Gel will be available for sale shortly," commented Igor Lokot, CEO of Double Bond Pharmaceutical and Drugsson AB. "We are continuing to look for new, sought after products that may be of interest to Drugsson's pipe-line."
More about Pileseptin: It's a new treatment for hemorrhoids that works effectively by reducing swelling and keeping the area clean from bacteria and dirt. Pileseptin Spray is used against external hemorrhoids and Pileseptin Gel against internal hemorrhoids. Pileseptin is the only product of its kind to abaite hemorrhoids and not just the symptoms.
More about Drugsson AB: www.drugsson.com
Full Company Name: Double Bond Pharmaceutical International AB (publ)
Corporate identity: 556991-6082
Stock short name: DBP B
Share ISIN code: SE0007185525
For more info, contact
Igor Lokot, CEO
Homepage: http://www.doublebp.com/
E-mail: info@doublebp.com
Blog: http://blog.doublebp.com
Follow us on LinkedIn, Facebook and Twitter!
Information on Double Bond Pharmaceutical International AB
DBP is a pharmaceutical company with the primary focus on development of therapies against cancer based on the company’s own developed drug delivery technology BeloGal®. The company was granted Orphan Drug Designation status by European Medicines Agency (EMA) in June 2015 for its first product, SA-033, for treatment of hepatoblastoma. Double Bond Pharmaceutical acquired rights to Temodex, a drug registered in Belarus for treatment of brain tumours, in October 2015, and was granted Orphan Drug Designation status by EMA for in July 2016 for this formulation of temozolomide for the treatment of glioma. The formulation is now being further developed for registration in EU and globally and has a working name SI-053 in DBP pipeline. DBP has during the past year also started two subsidiaries, Drugsson AB for the distribution of fully developed human pharmaceutical and medical device products and dietary supplements in Scandinavia, and FarmPharma AB for the development of innovative veterinary products.
Tags: